Business Context and Reporting Period
This Form 6-K filing by Addex Therapeutics Ltd. covers the month of April 2023, specifically dated April 4, 2023. The report details a capital raise event involving a registered direct offering, a concurrent private placement, and the repricing of existing warrants.
Key Financial Metrics and Capital Structure
- Offering Proceeds: Expected aggregate gross proceeds of $5.0 million before deducting offering expenses.
- Registered Direct Offering: Sale of 1,333,333 American Depositary Shares (ADSs) at $0.95 per ADS.
- Private Placement Warrants: Issuance of unregistered warrants to purchase up to 5,263,158 ADSs and unregistered pre-funded warrants to purchase up to 3,929,825 ADSs.
- Warrant Repricing: Exercise prices for previously issued warrants (Original 2021 and 2022 Warrants) were reduced from $6.50 and $1.90 per ADS, respectively, to $1.00 per ADS.
- Liquidity and Debt: The filing does not provide specific data on total cash balances, operating cash flow, net income, or outstanding debt levels.
Material Changes and Transaction Details
The primary material change is the execution of a securities purchase agreement on April 3, 2023, with a leading healthcare-focused institutional investor. Key transaction terms include:
- Closing Date: Expected on or about April 5, 2023.
- Warrant Terms: New unregistered warrants are exercisable 90 days post-issuance at $1.00 per ADS, expiring in five years. Pre-funded warrants are exercisable 60 days post-issuance at $0.01 per ADS.
- Amended Warrants: Existing warrants totaling 4,038,462 ADSs were amended to a $1.00 exercise price but are not exercisable until July 5, 2023.
- Lock-up and Participation: The Company agreed to a 60-day lock-up on new issuances and granted the purchaser a 50% participation right in future financings for 18 months.
Outlook, Risks, and Management Commentary
Management intends to file a Form F-1 registration statement to cover the resale of shares underlying the purchase warrants, which will allow them to become freely tradeable in the United States upon effectiveness. The filing notes that the offering is subject to customary closing conditions. No specific operational outlook, revenue guidance, or new risk factors beyond standard securities law disclosures were provided in this text.
Investor Verification Checklist
- Verify the actual closing date and final net proceeds after deducting offering expenses.
- Confirm the effectiveness of the Form F-1 resale registration statement for the warrant shares.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and exceptions to the lock-up period.
- Assess the dilution impact of the 1,333,333 new ADSs and the potential exercise of 9,192,983 warrant-covered ADSs.
- Check subsequent filings for the Company's updated cash position and runway following this capital raise.